Cocoa powder extracts exhibits hypolipidemic potential in cholesterol-fed rats

Hypercholesterolemia and oxidative stress are risk factors of cardiovascular diseases.

This study investigated the hypolipidemic effect of cocoa powder extract (CPE) in an experimental model of hypercholesterolemia, using Questran as a reference.

Hypercholesterolemia in rats was induced by oral administration of 30 mg/kg cholesterol for eight weeks. Three groups concurrently received Questran (0.26 g/kgb) and CPE (100 mg/kg and 200 mg/kg) respectively. Hypercholesterolemia and dyslipidemia were assessed by lipid profile. Reduced glutathione (GSH), Superoxide dismutase (SOD), Catalase (CAT), Glutathione-S-transferase (GST) and malondialdehyde (MDA) level were also assessed to evaluate the antioxidant status of rats.

There was 56% and 97% increase in total and LDL-cholesterol and 59% decrease in HDL-cholesterol levels on cholesterol administration. Concurrent administration of CPE (100 mg/kg) significantly (p < 0.05) decreased total cholesterol (19%) and LDL-cholesterol (22%) and increased HDL-cholesterol (286%) levels while at 200 mg/kg, 55% and 64% reductions in total and LDL-cholesterol and 250% increase in HDL-cholesterol levels were observed. No significant changes were observed in phospholipid levels. Body weights of rats were not significantly different among groups and CPE (100 mg/kg) ameliorated the cholesterol-induced enlargement of the liver and heart by 14% and 15% respectively and at 200 mg/kg by 21% in the heart. GSH and CAT were significantly depleted, and MDA and SOD significantly elevated in liver and heart of Cholesterol-fed rats. No significant changes in GST, alanine and aspartate aminotransferases occurred among groups. CPE treatment modulated these changes.

Cocoa powder possesses hypolipidemic potential and may be relevant in treating pathologies with dyslipidemia as an underlying cause.